This website uses cookies. For more information please contact us or consult our privacy policy.

Your binder contains too many pages, the maximum is 40.

We are unable to add this page to your binder, please try again later.

This page has been added to your binder.

Mark Johnson
Mark L. Johnson
Associate
Washington +1 202 662 5949 mjohnson@cov.com Download V-card

Mark L. Johnson practices corporate and securities law, with a focus on domestic and international capital-raising transactions, including initial public offerings and other equity and debt transactions. He also advises clients on a range of other corporate transactions and general corporate matters, including disclosure, compliance and corporate governance.

Mr. Johnson is a member of the New York bar. He is currently not admitted in the District of Columbia but is supervised by principals of the firm.

  • Represented Johnson & Johnson in multiple public offerings of investment-grade notes.
  • Represented the underwriters in the $150 million initial public offering and $215 million follow-on public offering of common stock of Kite Pharma, a biopharmaceutical company that genetically engineers a cancer patient’s T cells to recognize and destroy cancer cells.
  • Represented the underwriters in the initial public offering of Live Oak Bancshares, Inc., a bank holding company for its banking subsidiary Live Oak Bank, which focuses on the origination of short- and medium-term commercial and construction loans.
  • Represented the underwriters in the initial public offering and subsequent follow-on offering of Affimed N.V., a German-based clinical-stage biotechnology company focused on cancer immunotherapies.
  • Represented the underwriters in the $340 million public offering of shares of beneficial interests of Senior Housing Properties Trust, a real estate investment trust investing in health care and senior living facilities, which was followed by the public offering of $400 million of 3.25% Senior Notes and $250 million in 4.75% Senior Notes of Senior Housing by a different underwriting syndicate.
  • Represented the underwriters in several follow-on equity offerings for a biopharmaceutical company focused on cancer immunotherapies.
  • Represented the underwriters in several follow-on equity offerings for a molecular diagnostics company focused on early detection of colorectal cancer.
  • Representation of the sponsor in connection with the formation of a $400 million buyout fund focused on small and middle-market companies across a select group of industries that was structured as a series LLC.
  • Represented the underwriters in the $95 million follow-on public equity offering for Aratana Therapeutics, Inc., a biopharmaceutical pet therapeutics company, and four selling stockholders.